Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Table 1

Patients’ characteristics ().

Factor	Number
Age
Median (range)	70 (48–80)
Gender
Male	34
Female	8
ECOG performance status
0	32
1	10
HLA type
A24	24
A2	21
A3 supertype	14
A26	13
Clinical stage
IVa	15
IVb	27
JIS score
3	21
4	18
5	3
Previously conducted treatments
Locoregional
Hepatectomy	14
Surgery other than hepatectomy	2
Radiation	9
Transcatheter arterial embolization (TAE)	23
Transcatheter arterial chemoembolization (TACE)	16
Hepatic arterial infusion chemotherapy (HAIC)	16
Radiofrequency ablation (RFA)	15
Percutaneous ethanol injection therapy (PEIT)	6
Microwave coagulation therapy (MCT)	3
Systemic
Sorafenib	21
5-FU based chemotherapies	6
Other clinical trials	9
AFP at first visit
Median (range), ng/mL	376 (3.7–103000)
DCP at first visit
Median (range), mAU/mL	2335 (11–778000)
Number of vaccinations
Median (range)	8 (3–8)
Combination therapy
None	30
Sorafenib	10
Chemotherapy	2

ECOG: Eastern Cooperative Oncology Group; JIS: Japanese integrated staging; AFP: -fetoprotein; DCP: des--carboxy prothrombin.